The compounds are oral small molecules based on three distinct mechanistic platforms: calcitonin gene-related peptide (CGRP) receptor antagonists, glutamate modulators, and myeloperoxidase inhibitors.

Alzheimer's disease is one of the world’s most prevalent brain disorders, being extremely difficult to treat. Alzheimer's ...